Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | |||
| Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
| Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
| Soliris | Eculizumab | Atypical hemolytic uremic syndrome | N/A | Complete | ||
| VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | |||
| Ibrance | Palbociclib | Withdrawn | ||||
| Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active | |||
| N/A | Nab-paclitaxel | Solid tumours | Active |
Last Updated : April 19, 2024